Valuation: GENFIT

Market Cap 506M 577M 466M 437M 819M 54.43B 836M 5.61B 2.17B 26.9B 2.17B 2.12B 93.28B P/E 2025
-3.06x
P/E 2026 * 53.4x
Enterprise Value 451M 515M 416M 389M 730M 48.54B 745M 5B 1.93B 23.99B 1.93B 1.89B 83.19B EV / Sales 2025
2.34x
EV / Sales 2026 * 4.82x
Free-Float
86.88%
Yield 2025 *
-
Yield 2026 * -
1 month-4.79%
3 months-6.62%
6 months+71.20%
Current year+64.13%
1 month 8.74
Extreme 8.74
9.18
Current year 5.2
Extreme 5.205
9.36
1 year 3.19
Extreme 3.19
9.36
3 years 3.19
Extreme 3.19
9.36
5 years 3.19
Extreme 3.19
9.36
10 years 3.19
Extreme 3.19
9.36
Manager TitleAgeSince
Chief Executive Officer 58 16/09/2019
Director of Finance/CFO 52 22/04/2021
Chief Tech/Sci/R&D Officer - 27/11/2025
Director TitleAgeSince
Chairman 70 16/06/2017
Director/Board Member 54 15/09/1999
Director/Board Member 58 16/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 577M
-0.48%+7.20%-5.08%+2.45% 46.2B
+2.19%+11.71%+385.81%+632.13% 38.71B
+2.53%+13.93%+20.85%-10.61% 31.9B
+1.65%+3.61%+9.98%+55.42% 31.12B
-4.16%-2.58%+8.74%+15.22% 23.77B
-0.32%+12.96% - - 16.2B
+1.37%+14.53%+71.80%+134.14% 15.05B
+1.00%+10.30%+13.31%+22.84% 13.74B
+3.63%+9.53%+104.07%+107.62% 13.42B
Average +0.74%+9.14%+76.18%+119.90% 25.57B
Weighted average by Cap. +0.75%+8.71%+86.69%+140.75%

Financials

2025 2026 *
Net sales 66.82M 76.2M 61.59M 57.66M 108M 7.19B 110M 740M 286M 3.55B 286M 280M 12.32B 95.2M 109M 87.75M 82.15M 154M 10.24B 157M 1.05B 408M 5.06B 408M 399M 17.55B
Net income -8.3M -9.47M -7.65M -7.16M -13.43M -893M -13.71M -91.98M -35.59M -441M -35.56M -34.78M -1.53B 18.31M 20.88M 16.87M 15.8M 29.62M 1.97B 30.24M 203M 78.48M 973M 78.4M 76.69M 3.38B
Net Debt -54.72M -62.41M -50.44M -47.22M -88.55M -5.89B -90.39M -606M -235M -2.91B -234M -229M -10.09B -46.87M -53.45M -43.2M -40.44M -75.84M -5.04B -77.42M -519M -201M -2.49B -201M -196M -8.64B
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
188
Trader
Investor
Global
Quality
ESG MSCI
-